Is USNA a good stock to buy right now?

Based on our 6-factor quantitative model, USANA HEALTH SCIENCES INC (USNA) receives a "Reduce" rating with a composite score of 44.0/100. It is ranked #3,026 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 38/100, Momentum 28/100. The timing signal is "Bearish". This is quantitative analysis only — not investment advice.

What is the stock rating for USNA?

USANA HEALTH SCIENCES INC (USNA) has a "Reduce" rating and 2-star score. The composite score of 44.0 ranks it #3,026 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is USNA in?

USANA HEALTH SCIENCES INC operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $318 million. It is classified as a small-cap stock.

Does USNA pay a dividend?

USNA does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is USNA's P/E ratio?

USNA has a trailing P/E ratio of 50.50x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is USNA?

USNA's quality factor score is 50/100. Gross margin: 78.0%. ROE: 1.2% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is USNA valued compared to peers?

USNA's value factor score is 38/100 (higher = cheaper). Key multiples: P/E 50.5x, EV/EBITDA 7.6x. Trading at a premium relative to peers.

What is USNA's debt level?

USNA's debt-to-equity ratio is 27%. Sector average: 32%. Low leverage suggests conservative financial management.

USNA has a beta of 0.81, meaning it tracks the market. Stability score: 55/100.

Does USNA have high short interest?

USNA's short interest factor score is 63/100 (higher = less short selling). Moderate short interest.

USNA Stock Analysis: Top Small-Cap Reduce (Score 44.0/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
USNA	-1.25%	+7.16%	+1.57%	-7.74%	-26.80%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-1.19%	+3.56%	+1.23%	-7.38%	-56.32%	-	-	-
Alpha vs Sector	+0.10%	+6.82%	+5.38%	-2.90%	-36.01%	-	-	-

Metric	USNA	Benchmark
P/E Ratio	50.5x	+114%
EV/EBITDA	7.6x	+19%
Price / Book	0.6x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
USNA USANA HEALTH SCIENCES INC	44	50	38	28	50.5x	1.2%	78.0%	0.5%	6.7%	27.0x	$318M

Key Ratio	TTM	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017
Gross Margin %	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%
Operating Margin %	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%	0.2%	0.1%
EBITDA Margin %	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%	0.1%
Net Margin %	0.0%	-0.0%	-0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
FCF Margin %	-29.9%	-	-2.4%	-	-	-	12.8%	15.5%	10.4%	11.8%	10.6%
ROE %	0.0%	-0.0%	-0.0%	0.1%	0.1%	0.3%	0.3%	0.1%	0.3%	0.3%	0.2%
ROA %	0.0%	-0.0%	-0.0%	0.1%	0.1%	0.2%	0.2%	0.1%	0.2%	0.2%	0.1%
ROIC %	7.2%	0.2%	0.3%	9.8%	14.8%	34.0%	107.5%	32.4%	98.8%	84.2%	90.2%

Key Ratio

TTM

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

Gross Margin %

0.8%

Operating Margin %

0.0%

0.1%

0.2%

0.1%

0.2%

0.1%

EBITDA Margin %

0.0%

0.1%

0.2%

0.1%

Net Margin %

0.0%

-0.0%

0.0%

0.1%

FCF Margin %

-29.9%

-2.4%

12.8%

15.5%

10.4%

11.8%

10.6%

ROE %

0.0%

-0.0%

0.1%

0.3%

0.1%

0.3%

0.2%

ROA %

0.0%

-0.0%

0.1%

0.2%

0.1%

0.2%

0.1%

ROIC %

7.2%

0.2%

0.3%

9.8%

14.8%

34.0%

107.5%

32.4%

98.8%

84.2%

90.2%

Line Item	TTM	2024	2023	2022	2021	2019	2018	2017	2016
	$913M	$855M	$921M	$1.2B	$1.1B	$1.1B	$1.2B	$1.0B	$1.0B
	—	$161M	$177M	$218M	—	—	—	—	—
	$712M	$693M	$744M	$969M	$926M	$873M	$989M	$868M	$826M
Gross Margin	78.0%	81.1%	80.8%	81.6%	81.6%	82.3%	83.1%	82.9%	82.1%
	—	$263M	$257M	$279M	—	—	—	—	—
Research & Development	—	$12M	$11M	$11M	—	—	—	—	—
Depreciation	—	—	—	—	$23M	$23M	$17M	$16M	$13M
Total Operating Expenses	—	$627M	$651M	$798M	—	—	—	—	—
	$35M	$66M	$93M	$170M	$176M	$146M	$188M	$133M	$139M
EBIT	$35M	$66M	$93M	$170M	$176M	$146M	$188M	$133M	$139M
EBITDA	$43M	$66M	$93M	$170M	$198M	$173M	$204M	$149M	$151M
Operating Margin	3.6%	7.8%	10.1%	14.3%	15.6%	13.8%	15.8%	12.7%	13.8%
EBITDA Margin	4.7%	7.8%	10.1%	14.3%	17.5%	16.3%	17.2%	14.2%	15.0%
	—	—	$262K	$57K	$507K	$66K	$36K	$46K	$444K
	—	$76M	$102M	$171M	—	—	—	—	—
Income Tax Expense	—	$34M	$39M	$54M	$53M	$50M	$65M	$72M	$39M
	$6M	$42M	$64M	$117M	$125M	$101M	$126M	$63M	$100M
Net Margin	0.5%	4.9%	6.9%	9.8%	11.0%	9.5%	10.6%	6.0%	9.9%
	$-0.36	$2.20	$3.31	$5.78	$5.89	$4.44	$5.24	$2.57	$4.14
Diluted EPS	$-0.36	$2.19	$3.30	$5.73	$5.89	$4.44	$5.24	$2.57	$4.14
Weighted Avg Basic	—	19M	19M	20M	—	—	—	—	—
Weighted Avg Diluted	—	19M	19M	20M	—	—	—	—	—

Line Item

TTM

2024

2023

2022

2021

2019

2018

2017

2016

$913M

$855M

$921M

$1.2B

$1.1B

$1.2B

$1.0B

—

$161M

$177M

$218M

—

$712M

$693M

$744M

$969M

$926M

$873M

$989M

$868M

$826M

Gross Margin

78.0%

81.1%

80.8%

81.6%

82.3%

83.1%

82.9%

82.1%

—

$263M

$257M

$279M

—

Research & Development

—

$12M

$11M

—

Depreciation

—

$23M

$17M

$16M

$13M

Total Operating Expenses

—

$627M

$651M

$798M

—

$35M

$66M

$93M

$170M

$176M

$146M

$188M

$133M

$139M

EBIT

$35M

$66M

$93M

$170M

$176M

$146M

$188M

$133M

$139M

EBITDA

$43M

$66M

$93M

$170M

$198M

$173M

$204M

$149M

$151M

Operating Margin

3.6%

7.8%

10.1%

14.3%

15.6%

13.8%

15.8%

12.7%

13.8%

EBITDA Margin

4.7%

7.8%

10.1%

14.3%

17.5%

16.3%

17.2%

14.2%

15.0%

—

$262K

$57K

$507K

$66K

$36K

$46K

$444K

—

$76M

$102M

$171M

—

Income Tax Expense

—

$34M

$39M

$54M

$53M

$50M

$65M

$72M

$39M

$6M

$42M

$64M

$117M

$125M

$101M

$126M

$63M

$100M

Net Margin

0.5%

4.9%

6.9%

9.8%

11.0%

9.5%

10.6%

6.0%

9.9%

$-0.36

$2.20

$3.31

$5.78

$5.89

$4.44

$5.24

$2.57

$4.14

Diluted EPS

$-0.36

$2.19

$3.30

$5.73

$5.89

$4.44

$5.24

$2.57

$4.14

Weighted Avg Basic

—

19M

20M

—

Weighted Avg Diluted

—

19M

20M

—

USANA HEALTH SCIENCES INC (USNA) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does USANA HEALTH SCIENCES INC Do?

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah. USANA HEALTH SCIENCES INC (USNA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Kevin G. Guest and employs approximately 1,900 people, headquartered in Salt Lake City, Utah. With a market capitalization of $318M, USNA is one of the notable companies in the Healthcare sector.

USANA HEALTH SCIENCES INC (USNA) Stock Rating — Reduce (April 2026)

As of April 2026, USANA HEALTH SCIENCES INC receives a Reduce rating with a composite score of 44.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.USNA ranks #3,026 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, USANA HEALTH SCIENCES INC ranks #440 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

USNA Stock Price and 52-Week Range

USANA HEALTH SCIENCES INC (USNA) currently trades at $18.11. The stock lost $0.23 (1.3%) in the most recent trading session. The 52-week high for USNA is $38.32, which means the stock is currently trading -52.7% from its annual peak. The 52-week low is $16.89, putting the stock 7.2% above its annual trough. Recent trading volume was 104K shares, suggesting relatively thin trading activity.

Is USNA Overvalued or Undervalued? — Valuation Analysis

USANA HEALTH SCIENCES INC (USNA) carries a value factor score of 38/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 50.50x, compared to the Healthcare sector average of 23.63x — a premium of 114%. The price-to-book ratio stands at 0.61x, versus the sector average of 2.75x. The price-to-sales ratio is 0.35x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, USNA trades at 7.56x EV/EBITDA, versus 6.34x for the sector.

At current multiples, USANA HEALTH SCIENCES INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

USANA HEALTH SCIENCES INC Profitability — ROE, Margins, and Quality Score

USANA HEALTH SCIENCES INC (USNA) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 1.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 0.9% versus the sector average of -33.1%.

On a margin basis, USANA HEALTH SCIENCES INC reports gross margins of 78.0%, compared to 71.5% for the sector. The operating margin is 3.6% (sector: -66.1%). Net profit margin stands at 0.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 6.7% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

USNA Debt, Balance Sheet, and Financial Health

USANA HEALTH SCIENCES INC has a debt-to-equity ratio of 27.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.23x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $145M.

USNA has a beta of 0.81, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for USANA HEALTH SCIENCES INC is 55/100, reflecting average volatility within the normal range for its sector.

USANA HEALTH SCIENCES INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, USANA HEALTH SCIENCES INC reported revenue of $913M and earnings per share (EPS) of $-0.36. Net income for the quarter was $6M. Gross margin was 78.0%. Operating income came in at $35M.

In Q3 2026, USANA HEALTH SCIENCES INC reported revenue of $214M and earnings per share (EPS) of $-0.36. Net income for the quarter was $-7M. Gross margin was 77.1%. Revenue grew 0.0% year-over-year compared to Q3 2025. Operating income came in at $1M.

In Q3 2025, USANA HEALTH SCIENCES INC reported revenue of $214M and earnings per share (EPS) of $-0.36. Net income for the quarter was $-7M. Gross margin was 77.1%. Revenue grew 6.7% year-over-year compared to Q3 2024. Operating income came in at $1M.

In Q2 2025, USANA HEALTH SCIENCES INC reported revenue of $236M and earnings per share (EPS) of $0.52. Net income for the quarter was $10M. Gross margin was 78.7%. Revenue grew 10.8% year-over-year compared to Q2 2024. Operating income came in at $17M.

Over the past 8 quarters, USANA HEALTH SCIENCES INC has demonstrated a growth trajectory, with revenue expanding from $213M to $913M. Investors analyzing USNA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

USNA Dividend Yield and Income Analysis

USANA HEALTH SCIENCES INC (USNA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

USNA Momentum and Technical Analysis Profile

USANA HEALTH SCIENCES INC (USNA) has a momentum factor score of 28/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 46/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

USNA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, USANA HEALTH SCIENCES INC (USNA) ranks #440 out of 838 stocks based on the Blank Capital composite score. This places USNA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing USNA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full USNA vs S&P 500 (SPY) comparison to assess how USANA HEALTH SCIENCES INC stacks up against the broader market across all factor dimensions.

USNA Next Earnings Date

No upcoming earnings date has been announced for USANA HEALTH SCIENCES INC (USNA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy USNA? — Investment Thesis Summary

The quantitative profile for USANA HEALTH SCIENCES INC suggests caution. The value score of 38/100 indicates premium valuation. Momentum is weak at 28/100, a headwind for near-term performance.

In summary, USANA HEALTH SCIENCES INC (USNA) earns a Reduce rating with a composite score of 44.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on USNA stock.

Related Resources for USNA Investors

Explore more research and tools: USNA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare USNA head-to-head with peers: USNA vs AZN, USNA vs SLGL, USNA vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

3 Consumer Stocks That Concern Us

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

USANA HEALTH SCIENCES INC (USNA) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does USANA HEALTH SCIENCES INC Do?

USANA HEALTH SCIENCES INC (USNA) Stock Rating — Reduce (April 2026)

USNA Stock Price and 52-Week Range

Is USNA Overvalued or Undervalued? — Valuation Analysis

USANA HEALTH SCIENCES INC Profitability — ROE, Margins, and Quality Score

USNA Debt, Balance Sheet, and Financial Health

USANA HEALTH SCIENCES INC Revenue and Earnings History — Quarterly Trend

USNA Dividend Yield and Income Analysis

USNA Momentum and Technical Analysis Profile

USNA vs Competitors — Healthcare Sector Ranking and Peer Comparison

USNA Next Earnings Date

Should You Buy USNA? — Investment Thesis Summary

Related Resources for USNA Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

3 Consumer Stocks That Concern Us

USANA CEO Kevin Guest Calls for Daily Health Routines on World Health Day

Shaklee Announces Appointment of New General Manager for Australia and New Zealand

United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last?

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Ignore